이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

혈액암 환자(MK-1026-003)에 대한 넴타브루티닙(MK-1026)의 효능 및 안전성

2026년 10월 23일 업데이트: Merck Sharp & Dohme LLC

혈액암 환자에서 MK-1026의 효능 및 안전성을 평가하기 위한 2상 연구

The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM).

연구 개요

상세 설명

This study will be performed in 2 parts: Dose Escalation and Confirmation (Part 1) and Cohort Expansion (Part 2). Following determination of the recommended phase 2 dose (RP2D) in Part 1, the study plans to proceed with Part 2 using 8 disease-specific expansion cohorts (Cohorts A to H).

연구 유형

중재적

등록 (추정된)

490

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Seoul, 대한민국, 03722
        • 모병
        • Severance Hospital Yonsei University Health System ( Site 2201)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +82222281972
      • Seoul, 대한민국, 06351
        • 모병
        • Samsung Medical Center ( Site 2200)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +82234106548
    • Central Jutland
      • Aarhus N, Central Jutland, 덴마크, 8200
        • 완전한
        • Aarhus University Hospital ( Site 0702)
    • North Denmark
      • Aalborg, North Denmark, 덴마크, 9000
        • 모병
        • Aalborg Universitetshospital ( Site 0703)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +45 97660000
    • Region Sjælland
      • Koege, Region Sjælland, 덴마크, 4600
        • 모병
        • Sjællands Universitetshospital Køge ( Site 0701)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +45 46323200
    • Region Syddanmark
      • Odense C, Region Syddanmark, 덴마크, 5000
        • 완전한
        • Odense University Hospital ( Site 0705)
    • Baden-Wurttemberg
      • Ulm, Baden-Wurttemberg, 독일, 89081
        • 모병
        • Universitaetsklinikum Ulm. ( Site 0906)
        • 연락하다:
          • Study Coordinator
          • 전화번호: + 49 731 500 45901
    • North Rhine-Westphalia
      • Cologne, North Rhine-Westphalia, 독일, 50937
        • 모병
        • Universitaetsklinikum Koeln ( Site 0901)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +4922147897046
      • Siegen, North Rhine-Westphalia, 독일, 57072
        • 완전한
        • St. Marien-Krankenhaus Siegen ( Site 0914)
    • Saxony
      • Dresden, Saxony, 독일, 01307
        • 모병
        • Universitaetsklinikum Carl Gustav Carus ( Site 0902)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 0049 351 458 5692
      • Brasov, 루마니아, 500052
        • 모병
        • Centrul de Diagnostic si Tratament Oncologic Brasov ( Site 1802)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 0729075567
      • Iași, 루마니아, 700483
        • 모병
        • Institutul Regional de Oncologie Iasi ( Site 1801)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 40374278811
    • Bucharest
      • Bucharest, Bucharest, 루마니아, 030171
        • 모병
        • Spitalul Clinic Colțea ( Site 1805)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 0040213874100
    • Constanța County
      • Ovidiu, Constanța County, 루마니아, 905900
        • 완전한
        • Ovidius Clinical Hospital ( Site 1804)
    • Arkansas
      • Springdale, Arkansas, 미국, 72762
        • 모병
        • Highlands Oncology Group ( Site 2728)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 479-872-8130
    • California
      • La Jolla, California, 미국, 92093-0698
        • 모병
        • University of California San Diego Moores Cancer Center ( Site 2717)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 858-534-5201
      • Torrance, California, 미국, 90502
        • 완전한
        • Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site 2724)
    • Colorado
      • Denver, Colorado, 미국, 80218
        • 모병
        • Colorado Blood Cancer Institute ( Site 2726)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 720-754-4800
    • Kentucky
      • Louisville, Kentucky, 미국, 40202
        • 완전한
        • The University of Louisville, James Graham Brown Cancer Center ( Site 2729)
    • Minnesota
      • Rochester, Minnesota, 미국, 55905
        • 모집하지 않고 적극적으로
        • Mayo Clinic - Rochester ( Site 2706)
    • New Jersey
      • East Brunswick, New Jersey, 미국, 08816
        • 모병
        • Astera Cancer Care ( Site 2732)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 732-672-6405
      • Hackensack, New Jersey, 미국, 07601
        • 모병
        • John Theurer Cancer Center at Hackensack University Medical Center ( Site 2704)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 551-996-3003
    • North Dakota
      • Fargo, North Dakota, 미국, 58102
        • 완전한
        • Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 2708)
    • Texas
      • Dallas, Texas, 미국, 75390
        • 모병
        • UT Southwestern-Harold C. Simmons Cancer Center ( Site 2730)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 972-695-9450
    • Washington
      • Spokane, Washington, 미국, 99208
        • 모병
        • Medical Oncology Associates (Summit Cancer Centers) ( Site 2710)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 509-462-2273
      • Rio de Janeiro, 브라질, 20231-050
        • 모병
        • Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0300)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +552132076564
      • São Paulo, 브라질, 01321-001
        • 모병
        • Hospital Paulistano - Amil Clinical Research ( Site 0311)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +551130161340
      • São Paulo, 브라질, 01321-001
        • 모집하지 않고 적극적으로
        • BP - A Beneficencia Portuguesa de São Paulo ( Site 0302)
    • São Paulo
      • São Paulo, São Paulo, 브라질, 05403-000
        • 모병
        • Hospital das Clinicas FMUSP-Pesquisa Clínica Hematologia ( Site 0303)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 551145737543
    • Canton Ticino
      • Bellinzona, Canton Ticino, 스위스, 6500
        • 모병
        • Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 2302)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +41918118540
    • Canton of Bern
      • Bern, Canton of Bern, 스위스, 3010
        • 모병
        • Inselspital Bern ( Site 2303)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +41316329023
      • Alicante, 스페인, 03010
        • 모병
        • Hospital General Universitario de Alicante ( Site 2007)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 965 93 30 00
      • Barcelona, 스페인, 08035
        • 모병
        • Hospital Universitari Vall d'Hebron ( Site 2001)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +34934893806
      • Madrid, 스페인, 28041
        • 모병
        • Hospital Universitario 12 de Octubre ( Site 2003)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +34917792809
      • Madrid, 스페인, 28222
        • 모병
        • Hospital Puerta de Hierro ( Site 2009)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +34911916000
    • Barcelona
      • L'Hospitalet de Llobregat, Barcelona, 스페인, 08908
        • 모병
        • Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 2000)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +34932607750
    • Castille and León
      • Salamanca, Castille and León, 스페인, 37007
        • 모병
        • Hospital Universitario de Salamanca ( Site 2002)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 34923 29 11 00x55974
    • La Coruna
      • A Coruña, La Coruna, 스페인, 15006
        • 모병
        • CHUAC-Complejo Hospitalario Universitario A Coruña ( Site 2005)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 34981178000
      • Caba, 아르헨티나, C1114AAN
        • 모병
        • FUNDALEU ( Site 0104)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 5411 48771046
      • Córdoba, 아르헨티나, X5016KEH
        • 모병
        • Hospital Privado Universitario de Córdoba ( Site 0107)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +541569634187
      • Mendoza, 아르헨티나, M5500AYB
        • 완전한
        • Fundacion Centro Oncologico de Integración Regional-Medical Oncology ( Site 0110)
    • Buenos Aires
      • Ciudad Autonoma de Buenos Aires, Buenos Aires, 아르헨티나, C1118AAT
        • 모병
        • Hospital Aleman ( Site 0102)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +541148277000
    • Buenos Aires F.D.
      • Buenos Aires, Buenos Aires F.D., 아르헨티나, C1431FWO
        • 모병
        • Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0103)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +541152990247
    • Santa Fe Province
      • Rosario, Santa Fe Province, 아르헨티나, S2000DEJ
        • 모병
        • Fundacion Estudios Clinicos ( Site 0112)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +54 0341 238 4171
      • Dublin, 아일랜드, Dublin 9
        • 모병
        • Beaumont Hospital ( Site 2900)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +35318092010
      • Limerick, 아일랜드, V94 F858
        • 모집하지 않고 적극적으로
        • University Hospital Limerick ( Site 2903)
      • Manchester, 영국, M20 4BX
        • 모병
        • The Christie NHS Foundation Trust ( Site 2602)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 01619561217
    • Bristol, City of
      • Bristol, Bristol, City of, 영국, BS2 8ED
        • 모병
        • Bristol Haematology and Oncology Centre ( Site 2610)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 01173426733
    • England
      • Nottingham, England, 영국, NG5 1PF
        • 모병
        • Nottingham University Hospitals NHS Trust. City Hospital Campus ( Site 2601)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +441159691169
      • Windsor, England, 영국, SL4 3HD
        • 모병
        • GenesisCare - Windsor ( Site 2608)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +447989474250
    • London, City of
      • London, London, City of, 영국, W1G 6AD
        • 모병
        • Sarah Cannon Research Institute UK ( Site 2612)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 02032195234
    • Oxfordshire
      • Oxford, Oxfordshire, 영국, OX4 6LB
        • 모병
        • GenesisCare - Oxford ( Site 2607)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +447989474250
    • Suffolk
      • Newmarket, Suffolk, 영국, CB8 7XN
        • 모병
        • GenesisCare - Cambridge ( Site 2611)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 01223 655145
    • Surrey
      • Sutton, Surrey, 영국, SM2 5PT
        • 모병
        • The Royal Marsden NHS Foundation Trust. ( Site 2606)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 020 8642 6011
      • Kyiv, 우크라이나, 03022
        • 모병
        • National Cancer Institute ( Site 2507)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +380672091427
    • Cherkasy Oblast
      • Cherkassy, Cherkasy Oblast, 우크라이나, 18009
        • 모집하지 않고 적극적으로
        • MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( Site 2509)
    • Ivano-Frankivsk Oblast
      • Ivano-Frankivsk, Ivano-Frankivsk Oblast, 우크라이나, 76008
        • 완전한
        • Communal non-profit enterprise "Regional clinical hospital o-Hematology Department ( Site 2510)
    • Lviv Oblast
      • Lviv, Lviv Oblast, 우크라이나, 79044
        • 모병
        • Instit. of Blood Transfusion Medicine of the National Academy ( Site 2506)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +380322352276
      • Afula, 이스라엘, 1834111
        • 모병
        • Ha Emek Medical Center ( Site 1305)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 972-46494052
      • Beersheba, 이스라엘, 8410101
        • 모병
        • Soroka Medical Center ( Site 1307)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +97286403827
      • Haifa, 이스라엘, 3109601
        • 모병
        • Rambam Medical Center ( Site 1301)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +97247772547
      • Jerusalem, 이스라엘, 9112001
        • 모병
        • Hadassah Ein Karem Jerusalem ( Site 1300)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +97226778180
      • Ramat Gan, 이스라엘, 5262001
        • 모병
        • Chaim Sheba Medical Center ( Site 1302)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +97235308401
      • Rehovot, 이스라엘, 76100
        • 모병
        • Kaplan Medical Center ( Site 1304)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +97289441726
      • Tel Aviv, 이스라엘, 6423906
        • 모병
        • Sourasky Medical Center ( Site 1303)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +97236973782
      • Bari, 이탈리아, 70124
        • 완전한
        • Istituto Tumori Giovanni Paolo II ( Site 1409)
      • Bologna, 이탈리아, 40138
        • 모병
        • A.O. Universitaria Policlinico S. Orsola-Malpighi ( Site 1400)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +390516363680
      • Brescia, 이탈리아, 25123
        • 모병
        • ASST Spedali Civili di Brescia ( Site 1408)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +39 0303996416
      • Milan, 이탈리아, 20132
        • 모병
        • IRCCS Ospedale San Raffaele ( Site 1402)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 00390226434797
      • Naples, 이탈리아, 80131
        • 모병
        • Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1403)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +39 0815903 382
      • Pavia, 이탈리아, 27100
        • 모병
        • Fondazione IRCCS Policlinico San Matteo ( Site 1407)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +39 0382503084
      • Reggio Emilia, 이탈리아, 42123
        • 모병
        • IRCCS - Arcispedale Santa Maria Nuova ( Site 1405)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +39 0522295654
      • Roma, 이탈리아, 00161
        • 완전한
        • Policlinico Umberto I ( Site 1404)
    • Anhui
      • Hefei, Anhui, 중국, 230071
        • 모집하지 않고 적극적으로
        • Anhui Provincial Hospital ( Site 2808)
    • Beijing Municipality
      • Beijing, Beijing Municipality, 중국, 100191
        • 모병
        • Peking University Third Hospital-Hematology ( Site 2827)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 010-82266699
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, 중국, 400072
        • 모집하지 않고 적극적으로
        • The Second Affiliated Hospital of Chongqing Medical University ( Site 2825)
    • Guangdong
      • Guangzhou, Guangdong, 중국, 510060
        • 모집하지 않고 적극적으로
        • Sun Yat-sen University Cancer Center-Internal Medicine ( Site 2824)
    • Guangxi
      • Liuzhou, Guangxi, 중국, 545006
        • 모병
        • Liuzhou People's Hospital ( Site 2817)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +8607722662950
      • Nanning, Guangxi, 중국, 530028
        • 모병
        • Guangxi Medical University Cancer Hospital ( Site 2814)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +8607715323174
    • Henan
      • Zhengzhou, Henan, 중국, 450008
        • 모병
        • Henan Cancer Hospital-hematology department ( Site 2802)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 0371-65588007
    • Hubei
      • Wuhan, Hubei, 중국, 430022
        • 모병
        • Wuhan Union Hospital ( Site 2816)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +8618627091655
    • Hunan
      • Changsha, Hunan, 중국, 410011
        • 모병
        • The Second Xiangya Hospital of Central South University ( Site 2820)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +8613975806137
      • Changsha, Hunan, 중국, 410013
        • 모병
        • Hunan Cancer Hospital ( Site 2822)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 0731-88651669
    • Jiangsu
      • Nanjing, Jiangsu, 중국, 210029
        • 모병
        • Jiangsu Province Hospital ( Site 2823)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 025-86211033
      • Xuzhou, Jiangsu, 중국, 221000
        • 완전한
        • The Affiliated Hospital of Xuzhou Medical College ( Site 2818)
    • Jiangxi
      • Nanchang, Jiangxi, 중국, 330006
        • 모병
        • The First Affiliated Hospital of Nanchang University ( Site 2815)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 13970038386
    • Jilin
      • Changchun, Jilin, 중국, 130021
        • 모병
        • The First Hospital of Jilin University-Hematology ( Site 2803)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 0431-88786014
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, 중국, 200032
        • 모병
        • Fudan University Shanghai Cancer Center ( Site 2801)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +8602164175590
      • Shanghai, Shanghai Municipality, 중국, 200040
        • 모병
        • Huashan Hospital, Fudan University ( Site 2821)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 021-52889999
    • Sichuan
      • Chengdu, Sichuan, 중국, 610041
        • 모병
        • West China Hospital Sichuan University ( Site 2810)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +86028-85422114
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, 중국, 301617
        • 모병
        • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Unio ( Site 2800)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +8615900265415
    • Zhejiang
      • Hangzhou, Zhejiang, 중국, 310002
        • 모병
        • The First Affiliated Hospital, Zhejiang University ( Site 2826)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 057187236114
      • Hradec Králové, 체코, 500 05
        • 모병
        • Fakultni nemocnice Hradec Kralove ( Site 0601)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +420495832159
    • Brno-mesto
      • Brno, Brno-mesto, 체코, 625 00
        • 모병
        • Fakultní nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika ( Site 0600)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +420532233642
    • Alberta
      • Calgary, Alberta, 캐나다, T2N 5G2
        • 모병
        • Arthur J.E. Child Comprehensive Cancer Centre ( Site 0401)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 4035213723
    • Ontario
      • Ottawa, Ontario, 캐나다, K1H 8L6
        • 모병
        • The Ottawa Hospital ( Site 0404)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 613 737-7700
      • Toronto, Ontario, 캐나다, M5G 2M9
        • 모병
        • Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0406)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 416-946-2827
    • Quebec
      • Montreal, Quebec, 캐나다, H3T 1E2
        • 모병
        • Jewish General Hospital ( Site 0400)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 5143408222 x 24572
      • Montreal, Quebec, 캐나다, H1T 2M4
        • 모병
        • CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0403)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 5142523400
      • Ankara, 터키 (Türkiye), 06590
        • 모병
        • Ankara Universitesi Tip Fakultesi Cebeci Hastanesi ( Site 2400)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +903125957099
      • Istanbul, 터키 (Türkiye), 34365
        • 완전한
        • VKV Amerikan Hastanesi ( Site 2403)
      • Istanbul, 터키 (Türkiye), 34381
        • 모병
        • Sisli Florence Nightingale Hastanesi ( Site 2407)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +90 542 502 50 75
      • Izmir, 터키 (Türkiye), 35340
        • 모집하지 않고 적극적으로
        • Dokuz Eylül Üniversitesi-Hematology ( Site 2402)
    • Istanbul
      • Stanbul, Istanbul, 터키 (Türkiye), 34214
        • 모집하지 않고 적극적으로
        • Mega Medipol-Hematology ( Site 2406)
    • Lesser Poland Voivodeship
      • Krakow, Lesser Poland Voivodeship, 폴란드, 30-727
        • 모병
        • Pratia MCM Krakow ( Site 1601)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 48 12 2954135
    • Lower Silesian Voivodeship
      • Wroclaw, Lower Silesian Voivodeship, 폴란드, 50-367
        • 완전한
        • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu ( Site 1606)
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, 폴란드, 02-781
        • 모병
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Kilinka Onkologii I Hematologii ( Site 1608)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +48225462223
    • Opole Voivodeship
      • Opole, Opole Voivodeship, 폴란드, 45-061
        • 완전한
        • Szpital Wojewódzki w Opolu-Hematology Department ( Site 1607)
    • Pomeranian Voivodeship
      • Gdynia, Pomeranian Voivodeship, 폴란드, 81-519
        • 완전한
        • Szpitale Pomorskie Sp. z o.o. ( Site 1600)
      • Paris, 프랑스, 75010
        • 모병
        • Hopital Saint Louis ( Site 0805)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +33142499236
    • Alpes-Maritimes
      • Nice, Alpes-Maritimes, 프랑스, 06202
        • 모병
        • Centre Hospitalier Universitaire de Nice - Hôpital l'Archet ( Site 0810)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +33 4 92 03 57 85
    • Auvergne-Rhône-Alpes
      • Pierre-Bénite, Auvergne-Rhône-Alpes, 프랑스, 69495
        • 모병
        • Centre Hospitalier Lyon-Sud ( Site 0804)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +33478864348
    • Bouches-du-Rhone
      • Marseille, Bouches-du-Rhone, 프랑스, 13009
        • 모병
        • Institut Paoli-Calmettes ( Site 0803)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +33491223537
    • Yvelines
      • Le Chesnay, Yvelines, 프랑스, 78150
        • 완전한
        • Centre Hospitalier de Versailles ( Site 0809)
      • Budapest, 헝가리, 1122
        • 모병
        • Orszagos Onkologiai Intezet ( Site 1200)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +3612248600
    • Baranya
      • Pécs, Baranya, 헝가리, 7624
        • 모병
        • Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar ( Site 1202)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +3672536000
    • Hajdú-Bihar
      • Debrecen, Hajdú-Bihar, 헝가리, 4032
        • 모병
        • Debreceni Egyetem Klinikai Kozpont ( Site 1201)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +3652255196
    • Szabolcs-Szatmár-Bereg
      • Nyíregyháza, Szabolcs-Szatmár-Bereg, 헝가리, 4400
        • 모병
        • Szabolcs Szatmár Bereg Vármegyei Oktatókórház ( Site 1206)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +3642599700
    • New South Wales
      • Sydney, New South Wales, 호주, 2747
        • 완전한
        • Nepean Hospital-Nepean Cancer Care Centre ( Site 0204)
    • Victoria
      • Box Hill, Victoria, 호주, 3128
        • 모병
        • Box Hill Hospital ( Site 0203)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +611300342255
    • Western Australia
      • Nedlands, Western Australia, 호주, 6009
        • 모병
        • Sir Charles Gairdner Hospital ( Site 0200)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +61864573333

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days before C1D1 (the first dose of study treatment)
  • Has a life expectancy of at least 3 months, based on the investigator assessment
  • Has the ability to swallow and retain oral medication
  • Participants who are Hepatitis B surface antigen (HBsAg)-positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization
  • Participants with history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening
  • Has adequate organ function
  • Male participants agree to refrain from donating sperm and agree to either remain abstinent from penile-vaginal intercourse as their preferred and usual lifestyle OR agree to use contraception, during the intervention period and for at least the time required to eliminate the study intervention after last dose of study intervention
  • Female participants assigned female sex at birth who are not pregnant or breastfeeding are eligible to participate if not a participant of childbearing potential (POCBP), or if a POCBP they either use a contraceptive method that is highly effective OR remain abstinent from penile-vaginal intercourse as their preferred and usual lifestyle during the intervention period and for at least to eliminate study intervention after the last dose of study intervention
  • Participants with Human immunodeficiency virus (HIV) are eligible if they meet all of the following: the CD4 count is >350 cells/uL at screening, the HIV viral load is below the detectable level, are on a stable ART regimen for at least 4 weeks prior to study entry, and are compliant with their ART

Part 1 and Part 2 (Cohorts A to C and J)

  • Has a confirmed diagnosis of Chronic lymphocytic leukemia/ Small lymphocytic lymphoma (CLL/SLL) with

    • At least 2 lines of prior therapy (Part 1 only)
    • Part 2 Cohort A: CLL/SLL participants who are relapsed or refractory to prior therapy with a covalent, irreversible Bruton's tyrosine kinase inhibitor (BTKi), and a B-cell lymphoma 2 inhibitor (BCL2i). CLL participants must have received and failed, been intolerant to, or determined by their treating physician to be a poor phosphoinositide 3-kinase inhibitor (PI3Ki) candidate or ineligible for a PI3Ki per local guidelines
    • Part 2 Cohort B: CLL/SLL participants who are relapsed or refractory following at least 1 line of prior therapy and are BTKi treatment naive
    • Part 2 Cohort C: CLL/SLL participants with 17p deletion or tumor protein p53 (TP53) mutation who are relapsed or refractory following at least 1 line of prior therapy
    • Part 2 Cohort J: CLL/SLL participants whose disease relapsed or was refractory to prior therapy with a covalent/irreversible BTKi and BCL2i. NOTE: As of Protocol Amendment 09, at least 10 CLL/SLL participants whose disease relapsed or was refractory to prior therapy with a covalent/irreversible BTKi, BCL2i and noncovalent/reversible BTKi (all three classes of therapies are required) will be enrolled into Cohort J
    • Has active disease for CLL/SLL clearly documented to initiate therapy
    • For SLL participants in Part 2: Has evaluable core or excisional lymph node biopsy for biomarker analysis from an archival or newly obtained biopsy or bone marrow aspirate at Screening (optional for participants enrolling in Part 1)

Part 2 (Cohorts D to G)

- Has a confirmed diagnosis of and meets the following prior therapy requirements:

  • Participants with Richter's transformation who are relapsed or refractory following at least 1 line of prior therapy (Cohort D)
  • Participants with pathologically confirmed Mantle-cell lymphoma (MCL), documented by either overexpression of cyclin D1 or t (11;14), who are relapsed or are refractory to chemoimmunotherapy and a covalent irreversible BTKi (Cohort E)
  • Participants with Marginal zone lymphoma (MZL) (including splenic, nodal, and extra nodal MZL) who are relapsed or refractory to at least one prior line of systemic therapy including an anti-CD20-based regimen
  • Participants with Follicular lymphoma (FL) who are relapsed or refractory to chemoimmunotherapy and immunomodulatory agents (such as lenalidomide based regimen) (Cohort G)
  • Have measurable disease defined as at least 1 lesion that can be accurately measured in at least 2 dimensions with spiral Computed tomography (CT) scan
  • Has a lymph node biopsy for biomarker analysis from an archival or newly obtained biopsy or bone marrow aspirate (Cohort D) at Screening

Part 2 (Cohort H): confirmed diagnosis of Waldenström's macroglobulinemia (WM); participants who are relapsed or refractory to standard therapies for WM including chemoimmunotherapy and a covalent irreversible BTKi

  • Has active disease defined as 1 of the following: systemic symptoms, physical findings, laboratory abnormalities, coexisting disease
  • Has measurable disease, satisfying any of the following: at least 1 lesion that can be accurately measured in at least 2 dimensions with spiral CT scan (minimum measurement must be >15 mm in the longest diameter or >10 mm in the short axis); IgM ≥450 mg/dL; or bone marrow infiltration of 10%
  • Has fresh bone marrow aspirate or a lymph node biopsy for biomarker analysis at Screening or a lymph node biopsy from an archival

Exclusion Criteria:

  • Has active HBV/HCV infection (Part 1 and Part 2)
  • Has a history of malignancy ≤3 years before providing documented informed consent. Participants with basal cell carcinoma of skin, squamous cell carcinoma of skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potential curative therapy are not excluded. Participants with low-risk, early-stage prostate cancer (T1-T2a, Gleason score ≤6, and prostate-specific antigen <10 ng/mL) either treated with definitive intent or untreated in active surveillance with SD are not excluded
  • Has active central nervous system (CNS) disease
  • Has an active infection requiring systemic therapy
  • Has received prior systemic anti-cancer therapy within 5 half-lives or 4 weeks (if prior therapy was a monoclonal antibody) before C1D1
  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention
  • Has any clinically significant gastrointestinal abnormalities that might alter absorption
  • History of severe bleeding disorders

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Nemtabrutinib

Participants receive nemtabrutinib orally once daily (QD) until progressive disease (PD) or discontinuation.

Nemtabrutinib tablets administered orally QD.

다른 이름들:
  • MK-1026
  • ARQ 531

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Part 1: Number of participants experiencing dose-limiting toxicities (DLTs)
기간: Up to ~56 days (Cycles 1-2, cycle = 28 days)

DLTs will be defined as toxicities observed during the first 2 cycles (8 weeks) of Part 1 and include: Grade ≥3 nonhematologic toxicity (except Grade 3 nausea, vomiting, diarrhea, rash, fatigue, and uncontrolled hypertension which will not be considered a DLT unless lasting ≥72 hours despite optimal supportive care); Grade 4 hematologic toxicity lasting >7 days (except Grade 3 lymphocytosis, Grade 4 platelet count decreased of any duration, or Grade 3 platelet count decreased if associated with bleeding); any Grade 3 or Grade 4 nonhematologic laboratory abnormality if values result in drug-induced liver injury, or medical intervention is required, or the abnormality leads to hospitalization, or the abnormality persists for >1 week (with exceptions); missing >25% of nemtabrutinib doses as a result of drug-related adverse events (AEs) during the first 2 cycles (8 weeks); Grade 5 toxicity.

Up to ~56 days (Cycles 1-2, cycle = 28 days)
Part 1: Number of participants experiencing adverse events (AEs)
기간: Up to ~71 months

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing AEs will be reported for Part 1.

Up to ~71 months
Part 1: Number of participants discontinuing study treatment due to AEs
기간: Up to ~42 months

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants discontinuing study treatment due to an AE will be reported for Part 1.

Up to ~42 months
Part 2: Objective Response Rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria 2018 as assessed by independent central review (ICR)
기간: Up to ~61 months

ORR per iwCLL 2018 criteria is defined as the percentage of participants achieving a complete response (CR), complete response with incomplete bone marrow recovery (CRi), nodular partial response (nPR), or partial response (PR). CR is defined as meeting the following criteria: no lymph nodes >1.5 cm, spleen size <13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10^9/L or ≥50% increase from screening, hemoglobin >11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow.

Up to ~61 months
Part 2: ORR per Lugano criteria 2014 as assessed by ICR
기간: Up to ~61 months

ORR per Lugano criteria 2014 is defined as the percentage of participants achieving a CR or PR. CR defined as EITHER CR by imaging (computed tomography [CT]): all lymph nodes normal (none ≥15 mm) and normal liver and spleen OR complete metabolic response (CMR): score of 1, 2 or 3 on the 5-point scale assessing fluorodeoxyglucose (FDG) metabolic activity in lymphomatous lesions (ranging from 1=no uptake above background to 5=uptake markedly higher than liver) AND bone marrow (BM) normal by morphology. PR defined as EITHER PR by imaging (CT) with ≥50% decrease in the sum of the product of diameters [SPD] of target lesions, no worsening of nontarget lesions, no new lesions and ≥50% spleen abnormal portion OR Partial Metabolic Response (PMR) with score of 4 or 5 on the FDG 5-point scale (with no new lesions) and decreased overall uptake AND residual BM abnormalities; OR CR by imaging with residual BM abnormalities; OR PR by imaging without residual BM abnormalities.

Up to ~61 months
Part 2: ORR per International Workshop on Waldenström's Macroglobulinemia (IWWM) criteria 2014 as assessed by ICR
기간: Up to ~71 months

ORR per IWWM criteria 2014 is defined as the percentage of participants achieving a CR, very good partial response (VGPR), or PR. CR is defined as all lymph nodes are normal in size (none ≥15 mm), liver and spleen normal in size, serum immunoglobulin M (IgM) values in the normal range, disappearance of monoclonal protein by immunofixation (confirmation needed with a second immunofixation at any subsequent timepoint), and no histological evidence of BM involvement. VGPR is defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in the abnormal portion of the spleen (if previously abnormal), and ≥90% decrease from baseline in serum IgM, or serum IgM values in normal range. PR is defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in serum IgM, and ≥50% decrease from baseline in the abnormal portion of the spleen (if previously abnormal).

Up to ~71 months

2차 결과 측정

결과 측정
측정값 설명
기간
Part 1: Area Under the Curve (AUC) of Nemtabrutinib
기간: At designated time points (up to ~57 days)

Blood samples will be obtained at designated time points during Part 1 for the assessment of nemtabrutinib AUC (Day 1 of Cycles 1 and 2: Pre-dose, 2, 4, 6, 8, and 24 hours post-dose; Day 1 of Cycle 3: pre-dose and 2, 4, and 6 hours post-dose [up to ~57 days]). Each cycle is 28 days.

At designated time points (up to ~57 days)
Part 1: Minimum Concentration (Cmin) of Nemtabrutinib
기간: At designated time points (up to ~57 days)

Blood samples will be obtained at designated time points during Part 1 for the assessment of nemtabrutinib Cmin (Day 1 of Cycles 1 and 2: Pre-dose, 2, 4, 6, 8, and 24 hours post-dose; Day 1 of Cycle 3: pre-dose and 2, 4, and 6 hours post-dose [up to ~57 days]). Each cycle is 28 days.

At designated time points (up to ~57 days)
Part 1: Maximum Concentration (Cmax) of Nemtabrutinib
기간: At designated time points (up to ~57 days)

Blood samples will be obtained at designated time points during Part 1 for the assessment of nemtabrutinib Cmax (Day 1 of Cycles 1 and 2: Pre-dose, 2, 4, 6, 8, and 24 hours post-dose; Day 1 of Cycle 3: pre-dose and 2, 4, and 6 hours post-dose [up to ~57 days]). Each cycle is 28 days.

At designated time points (up to ~57 days)
Part 1: ORR per iwCLL criteria 2018 as assessed by ICR
기간: Up to ~71 months

ORR per iwCLL 2018 criteria is defined as the percentage of participants achieving a CR, CRi, nPR, or PR. CR is defined as meeting the following criteria: no lymph nodes >1.5 cm, spleen size <13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10^9/L or ≥50% increase from screening, hemoglobin >11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow.

Up to ~71 months
Part 1: Duration of Response (DOR) per iwCLL criteria 2018 as assessed by ICR
기간: Up to ~71 months

For participants with CR, CRi, nPR, or PR per iwCLL 2018 criteria, DOR is defined as the time from the first documented evidence of objective response until PD or death due to any cause, whichever occurs first. CR is defined as meeting the following criteria: no lymph nodes >1.5 cm, spleen size <13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10^9/L or ≥50% increase from screening, hemoglobin >11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow.

Up to ~71 months
Part 2: Number of participants experiencing AEs
기간: Up to ~61 months

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing AEs will be reported for Part 2.

Up to ~61 months
Part 2: Number of participants discontinuing study treatment due to AEs
기간: Up to ~42 months

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants discontinuing study treatment due to an AE will be reported for Part 2.

Up to ~42 months
Part 2: AUC of Nemtabrutinib
기간: At designated time points (up to ~57 days)

Blood samples will be obtained at designated time points during Part 2 for the assessment of nemtabrutinib AUC (Day 1 of Cycles 1, 2, and 3: Pre-dose, 2, 4, 6, hours post-dose [up to ~57 days]). Each cycle is 28 days.

At designated time points (up to ~57 days)
Part 2: Cmin of Nemtabrutinib
기간: At designated time points (up to ~57 days)

Blood samples will be obtained at designated time points during Part 2 for the assessment of nemtabrutinib Cmin (Day 1 of Cycles 1, 2, and 3: Pre-dose, 2, 4, 6, hours post-dose [up to ~57 days]). Each cycle is 28 days.

At designated time points (up to ~57 days)
Part 2: Cmax of Nemtabrutinib
기간: At designated time points (up to ~57 days)

Blood samples will be obtained at designated time points during Part 2 for the assessment of nemtabrutinib Cmax (Day 1 of Cycles 1, 2, and 3: Pre-dose, 2, 4, 6, hours post-dose [up to ~57 days]). Each cycle is 28 days.

At designated time points (up to ~57 days)
Part 2: DOR per iwCLL criteria 2018 as assessed by ICR
기간: Up to ~61 months

For participants with CR, CRi, nPR, or PR per iwCLL 2018 criteria, DOR is defined as the time from the first documented evidence of objective response until disease progression or death due to any cause, whichever occurs first. CR is defined as meeting the following criteria: no lymph nodes >1.5 cm, spleen size <13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10^9/L or ≥50% increase from screening, hemoglobin >11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow.

Up to ~61 months
Part 2: DOR per Lugano criteria 2014 as assessed by ICR
기간: Up to ~61 months

For participants with CR or PR per Lugano criteria 2014, DOR is defined as the time from the first documented evidence of objective response until PD or death due to any cause, whichever occurs first. CR defined as EITHER CR by imaging (CT): all lymph nodes normal (none ≥15 mm) and normal liver and spleen OR CMR: score of 1, 2 or 3 on the 5-point scale assessing FDG metabolic activity in lymphomatous lesions (ranging from 1=no uptake above background to 5=uptake markedly higher than liver and/or new lesions) AND BM normal by morphology. PR defined as EITHER PR by imaging (CT) with ≥50% decrease in the SPD of target lesions, no worsening of nontarget lesions, no new lesions and ≥50% spleen abnormal portion OR PMR with score of 4 or 5 on the FDG 5-point scale (with no new lesions) and decreased overall uptake AND residual BM abnormalities; OR CR by imaging with residual BM abnormalities; OR PR by imaging without residual BM abnormalities.

Up to ~61 months
Part 2: DOR per IWWM criteria 2014 as assessed by ICR
기간: Up to ~61 months

For participants with CR, VGPR, or PR per IWWM criteria 2014, DOR defined as the time from first documented evidence of objective response until PD or death due to any cause, whichever occurs first. CR defined as all lymph nodes normal in size (none ≥15 mm), liver and spleen normal in size, serum IgM values in normal range, disappearance of monoclonal protein by immunofixation (confirmation needed with second immunofixation at any subsequent timepoint), and no histological evidence of BM involvement. VGPR defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in abnormal portion of the spleen (if previously abnormal), and ≥90% decrease from baseline in serum IgM, or serum IgM values in normal range. PR is defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in serum IgM, and ≥50% decrease from baseline in abnormal portion of the spleen (if previously abnormal).

Up to ~61 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 책임자: Medical Director, Merck Sharp & Dohme LLC

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 4월 5일

기본 완료 (추정된)

2029년 1월 4일

연구 완료 (추정된)

2029년 1월 4일

연구 등록 날짜

최초 제출

2021년 1월 25일

QC 기준을 충족하는 최초 제출

2021년 1월 25일

처음 게시됨 (실제)

2021년 1월 28일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 27일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 23일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다